Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)

Psoriasis, a chronic, immune‐mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to evaluate the long‐term efficacy and safety of ixekizumab, a humanized, anti‐interleukin‐17A monoclonal antibody, in J...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Dermatol
Κύριοι συγγραφείς: Saeki, Hidehisa, Nakagawa, Hidemi, Nakajo, Ko, Ishii, Taeko, Morisaki, Yoji, Aoki, Takehiro, Cameron, Gregory S., Osuntokun, Olawale O., Akasaka, Toshihide, Asano, Yoshihide, Etoh, Takafumi, Fujita, Yasuyuki, Hashimoto, Takashi, Higashiyama, Mari, Igarashi, Atsuyuki, Ihn, Hironobu, Iwatsuki, Keiji, Kabashima, Kenji, Kawada, Akira, Kawashima, Makoto, Nakamura, Koichiro, Okubo, Yukari, Okuyama, Ryuhei, Ozawa, Akira, Sayama, Koji, Seishima, Mariko, Shiohara, Tetsuo, Takahara, Masakazu, Takahashi, Hidetoshi, Takehara, Kazuhiko, Tanese, Keiji, Tani, Mamori, Umezawa, Yoshinori, Watanabe, Hideaki, Yamanaka, Keiichi
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2016
Θέματα:
Original Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412888/
https://ncbi.nlm.nih.gov/pubmed/27726163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.13622
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
Φορτώνει......

Παρόμοια τεκμήρια